Pluristem Therapeutics Inc. news

   Watch this stock
Showing stories 1 - 10 of about 92   

Articles published

PSTI 2.82 -0.05 (-1.74%)
price chart
MLV Maintains Buy on Pluristem Therapeutics Inc. as PLX-R18 Strategy ...
In a research report published Tuesday, MLV analyst Vernon Bernardino maintained a Buy rating on Pluristem Therapeutics Inc. (NASDAQ:PSTI) with a price target of $6.00, which represents a potential upside of 113% from where the stock is currently ...
Pluristem Therapeutics: A Biotech Scam Promoted By A Bucket Shop
Pluristem Therapeutics Inc. (NASDAQ:PSTI) is a clinical-stage company engaged in development of cell therapy products for the treatment of life threatening diseases.
Pluristem Therapeutics (PSTI) Reports Data from Phase I/II PLX-PAD Trail
Pluristem Announces Significant New Finding From Its Phase I/II Muscle ...  GlobeNewswire (press release)
Pluristem Therapeutics, Inc. (PSTI) in Focus: Stock Up 7.4%
Pluristem Therapeutics, Inc. was a big mover last session, as the company saw its shares rise over 7% on the day. This rally higher can be attributable to solid volume too with far more shares changing hands than in a normal session.
Pluristem Therapeutics Inc. (NASDAQ:PSTI) a Buy: MLV & Co
In a research note issued to investors, Vernon Bernardino at MLV & Co Reiterated their Buy rating on Pluristem Therapeutics Inc. (NASDAQ:PSTI). The analyst placed a $6.00 price target on the stock which indicates a 105.48% upside to the last closing price.
Thursday's Pre-Market Information: Pluristem Therapeutics, Inc. (PSTI ...  WallStreet Scope
Pluristem Therapeutics Inc. (PSTI): The Bull Case For Pluristem Therapeutics
One of the problems that the technology faced was that the cell culture process created degradation in the quality of their therapeutic ability.
Related articles »  
Top Stories in Biotech This Morning: Pluristem Therapeutics, Inc, Rigel ...
This is the second regulatory approval for the company's 3D cell manufacturing process, having received approval in Germany last January.
Related articles »  
Pluristem surges on bullish research report (PSTI)
Thinly-traded micro cap Pluristem Therapeutics (NASDAQ:PSTI) is up 11% premarket on robust volume in apparent response to a bullish report from Acceleron equity research with a price target of $21.
Pluristem Therapeutics (PSTI) in Focus: Stock Surges 20.4%
Pluristem Therapeutics, Inc. was a big mover last session, as the company saw its shares rise more than 20% on the day.
Pluristem Therapeutics Inc. (PSTI) news: Pluristem's Preeclampsia Effort ...
The power of the placenta rings truer than ever in an upcoming therapeutic indication planned by Pluristem Therapeutics, Inc. (NASDAQ:PSTI) using PLX cell therapy for treating pregnant women with preeclampsia, a leading cause of maternal and infant ...
Related articles »  
Pluristem Therapeutics Inc. (PSTI): Mesoblast Is No Match For Pluristem's IP ...
Last week, Pluristem Therapeutics Inc. (NASDAQ:PSTI) won a method of use patent in Australia for its PLX cells in ischemia, where obstruction of blood vessels to an organ causes tissue death.
Related articles »